Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Rachel M. Squillace"'
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55a658107edbacb04f85646bc213606
https://doi.org/10.1158/1535-7163.22496250.v1
https://doi.org/10.1158/1535-7163.22496250.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569b6d231c9801039f6c0365f86e4e7
https://doi.org/10.1158/1535-7163.c.6535203
https://doi.org/10.1158/1535-7163.c.6535203
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31157ac1340d347481ad2e92f31f6667
https://doi.org/10.1158/1535-7163.22496256
https://doi.org/10.1158/1535-7163.22496256
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, David Clapham, Lauren Moran, Scott D. Wardwell, Michelle Cookson, David Miller, Rachel M. Squillace
Ridaforolimus is a nonprodrug rapamycin analogue that potently inhibits mTOR and has shown significant activity in patients with metastatic sarcoma and endometrial cancer, two diseases where high unmet need remains. Here, we evaluated the activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19b2a7bd378bf98a50c639945bcc5363
https://doi.org/10.1158/1535-7163.c.6535366
https://doi.org/10.1158/1535-7163.c.6535366
Autor:
Victor M. Rivera, Tim Clackson, Frank Wang, David Clapham, Lauren Moran, Scott D. Wardwell, Michelle Cookson, David Miller, Rachel M. Squillace
PDF file - 40K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192df8d186eba84431831e5abd6995f2
https://doi.org/10.1158/1535-7163.22496686
https://doi.org/10.1158/1535-7163.22496686
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439392f02e858cecdc3c943bce799317
https://doi.org/10.1158/1535-7163.22496247
https://doi.org/10.1158/1535-7163.22496247
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bf4f4d96fd3dfbf968b8c8066295f5
https://doi.org/10.1158/1535-7163.22496244.v1
https://doi.org/10.1158/1535-7163.22496244.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eeceb9b398b313ae4df947905f9c06b
https://doi.org/10.1158/1535-7163.22496253
https://doi.org/10.1158/1535-7163.22496253
Autor:
Hui H Zhang, Jingxiang Huang, Katrin Düvel, Bernard Boback, Shulin Wu, Rachel M Squillace, Chin-Lee Wu, Brendan D Manning
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6189 (2009)
BACKGROUND:The signaling pathways imposing hormonal control over adipocyte differentiation are poorly understood. While insulin and Akt signaling have been found previously to be essential for adipogenesis, the relative importance of their many downs
Externí odkaz:
https://doaj.org/article/a9f51988012940b29444ad496cd0ae26
Autor:
Lauren Moran, Wei-Sheng Huang, Yaoyu Ning, Dong Zou, Scott Wardwell, Emily Y. Ye, Frank Wang, Rachel M. Squillace, Lindsey W. Eichinger, Victor M. Rivera, Jeff Keats, Sen Zhang, William C. Shakespeare, Yihan Wang, Sara Nadworny, Shuangying Liu, Tianjun Zhou, Youngchul Song, Xiaotian Zhu, Tim Clackson, David Miller, Hyun Gyung Jang, Narayana I. Narasimhan, Rana Anjum, David C. Dalgarno, Qurish K. Mohemmad, Juan J. Miret
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(22)
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a954184cf0503cf7aa96ae269a34c3cb
https://pubmed.ncbi.nlm.nih.gov/27780853
https://pubmed.ncbi.nlm.nih.gov/27780853